AstraZeneca PLC
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pascal Claude Roland Soriot
- Full Time Employees
- 96,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 Francis Crick Avenue Cambridge CA United Kingdom CB2 0AA
- IPO Date
- May 12, 1993
- CIK
- 0000901832
- Website
- astrazeneca.com
- Similar Companies
- Business
- AstraZeneca PLC is a British-Swedish multinational biopharmaceutical company dedicated to the discovery, development, production, and worldwide commercialization of innovative prescription medicines. The company maintains a comprehensive portfolio of treatments spanning key therapeutic areas, including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, rare disease, and vaccines and immune therapies. Its innovative products serve a global patient population, reaching over 125 countries through a network of local marketing companies, distributors, and representative offices. The firm's operational focus centers on pioneering scientific breakthroughs to address significant unmet medical needs. AstraZeneca actively invests in research and development, evidenced by substantial annual expenditures aimed at advancing a robust pipeline of next-generation therapies. Recent strategic initiatives include ambitious goals for revenue growth, with an aim to launch 20 new medicines and achieve $80 billion in total revenue by 2030. AstraZeneca consistently engages in strategic partnerships and acquisitions to bolster its capabilities and pipeline. Notable collaborations include an expanded alliance with Harbour BioMed for next-generation biotherapeutics and a research agreement with CSPC Pharmaceutical Group for novel oral drug candidates. The company also recently invested $2 billion in a new Maryland manufacturing facility to establish cell therapy platforms, and its digital health solutions arm, Evinova, was launched in late 2023. Recent product advancements and approvals include Koselugo for neurofibromatosis type 1 in adults and positive Phase III results for Baxdrostat in resistant hypertension. AstraZeneca was established through the merger of Astra AB and Zeneca Group in 1999, and its headquarters are situated in Cambridge, United Kingdom.
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
Do Options Traders Know Something About AstraZeneca Stock We Don't?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
AstraZeneca may buck a decade of pharma strategy to buy U.S. scale
Deal or No Deal, AstraZeneca Stock Is a Bargain
180 Wealth Advisors LLC Invests $3.89 Million in Astrazeneca Plc $AZN
'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
Brokers split on AstraZeneca merger talk as shares recover some ground
Brokers split on AstraZeneca merger talk as shares recover some ground
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus
Bristol-Myers stock: why AstraZeneca merger is unlikely to happen
Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
Live Nasdaq Composite: Stock Market Bulls Wrestle Control to Start August as Oil Drops 6%
5 Things to Know Before the Stock Market Opens on Monday
Analysts baffled by AstraZeneca's interest in Bristol Myers Squibb
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday's Pre-Market Session